This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC)	PTK7 protein tyrosine kinase 7 (PTK7; CCK4)	Studies in mice and patient samples suggest inhibiting PTK7 could be useful for treating lung adenocarcinomas. In primary human lung adenocarcinoma samples, compared with normal lung tissue, PTK7 was overexpressed. In a mouse xenograft model of lung adenocarcinoma, shRNA against <i>PTK7</i> decreased tumor growth compared with control shRNA. Next steps could include screening for and evaluating pharmacological PTK7 inhibitors in mouse models of lung adenocarcinoma.	Patent and licensing status unavailable	Chen, R. <i>et al. Cancer Res.</i> ; published online March 20, 2014; doi:10.1158/0008-5472.CAN-13-2775 Contact: E. Alejandro Sweet-Cordero, Stanford University, Stanford, Calif. e-mail: ascor@stanford.edu
SciBX 7(16); doi:10.1038/scibx.2014.457 Published online April 24, 2014				